Indication
Fuchs Endothelial Corneal Dystrophy
10 clinical trials
11 products
1 drug
Product
EO2002Clinical trial
A Phase 1, Prospective, Multi-Center, Open-Label, Dose-Escalation Study to Assess the Safety, and Tolerability of EO2002 With and Without Endothelial Brushing or Descemet Stripping in the Treatment of Corneal Edema (EMME-001)Status: Active (not recruiting), Estimated PCD: 2024-10-30
Product
STN1010904Clinical trial
A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) - PHANTOM StudyStatus: Recruiting, Estimated PCD: 2025-03-01
Product
PlaceboClinical trial
Phase 2 Study To Determine the Safety and Efficacy of TTHX1114(NM141) on the Regeneration and Migration of Corneal Endothelial Cells in Patients Undergoing DWEK/DSOStatus: Completed, Estimated PCD: 2022-11-16
Product
TTHX1114(NM141)Clinical trial
A Phase 1/ Phase 2 Study Evaluating the Safety and Efficacy of the Investigational New Drug TTHX1114(NM141) on the Regeneration of Corneal Endothelial Cells in Patients With Corneal Endothelial Dystrophies Following Intracameral DeliveryStatus: Completed, Estimated PCD: 2021-04-23
Clinical trial
Descemet Endothelial Thickness Comparison Trials (DETECT I & II)Status: Recruiting, Estimated PCD: 2026-11-30
Product
RipasudilClinical trial
Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal DystrophyStatus: Recruiting, Estimated PCD: 2024-05-01
Product
N-acetyl cysteineProduct
Visine Dry Eye ReliefClinical trial
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects With Fuchs Endothelial Corneal DystrophyStatus: Recruiting, Estimated PCD: 2024-06-01
Drug
VarlilumabClinical trial
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects With Fuchs Endothelial Corneal DystrophyStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Analysis of the Genotype/Phenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France. The French Fuchs' Follow-up Study, F3SStatus: Completed, Estimated PCD: 2020-11-10
Product
Blood SampleClinical trial
The Evaluation of Balanced Salt Solution During Cataract SurgeryStatus: Recruiting, Estimated PCD: 2023-12-01
Product
BSS PlusProduct
BSS